SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-21-021672
Filing Date
2021-04-15
Accepted
2021-04-15 13:49:33
Documents
6
Period of Report
2021-04-14
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea139552-8k_immucellcorp.htm 8-K 19353
2 OPINION OF PIERCE ATWOOD LLP ea139552ex5-1_immucellcorp.htm EX-5.1 9908
3 SECURITIES PURCHASE AGREEMENT, DATED APRIL 14, 2021, BY AND AMONG IMMUCELL CORPO ea139552ex10-1_immucellcorp.htm EX-10.1 125638
4 PRESS RELEASE OF THE COMPANY DATED APRIL 14, 2021 ea139552ex99-1_immucellcorp.htm EX-99.1 13691
5 GRAPHIC ex5-1_001.jpg GRAPHIC 19051
6 GRAPHIC ex5-1_002.jpg GRAPHIC 17152
  Complete submission text file 0001213900-21-021672.txt   219813
Mailing Address 56 EVERGREEN DRIVE PORTLAND ME 04103
Business Address 56 EVERGREEN DR PORTLAND ME 04103 2078782770
IMMUCELL CORP /DE/ (Filer) CIK: 0000811641 (see all company filings)

IRS No.: 010382980 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12934 | Film No.: 21828089
SIC: 2835 In Vitro & In Vivo Diagnostic Substances